Simplicity Solutions LLC Increases Position in Hologic, Inc. (NASDAQ:HOLX)

Simplicity Solutions LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 4,576 shares of the medical equipment provider’s stock after acquiring an additional 274 shares during the quarter. Simplicity Solutions LLC’s holdings in Hologic were worth $327,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nordea Investment Management AB increased its holdings in shares of Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after purchasing an additional 69,494 shares in the last quarter. Pathstone Family Office LLC increased its holdings in Hologic by 96.0% during the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock valued at $643,000 after acquiring an additional 4,542 shares in the last quarter. Ontario Teachers Pension Plan Board increased its holdings in Hologic by 186.7% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock valued at $2,665,000 after acquiring an additional 25,010 shares in the last quarter. HB Wealth Management LLC increased its holdings in Hologic by 18.1% during the 3rd quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock valued at $401,000 after acquiring an additional 884 shares in the last quarter. Finally, McGuire Investment Group LLC increased its holdings in Hologic by 0.3% during the 4th quarter. McGuire Investment Group LLC now owns 139,161 shares of the medical equipment provider’s stock valued at $9,943,000 after acquiring an additional 366 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on HOLX shares. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Evercore ISI raised their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. UBS Group raised their target price on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Raymond James raised their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, William Blair restated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $87.00.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $75.38 on Friday. The company has a market cap of $17.69 billion, a PE ratio of 35.73, a price-to-earnings-growth ratio of 2.54 and a beta of 1.00. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The company has a 50-day simple moving average of $75.75 and a 200-day simple moving average of $72.54.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. During the same period last year, the company earned $1.07 earnings per share. The company’s quarterly revenue was down 5.7% on a year-over-year basis. On average, equities analysts anticipate that Hologic, Inc. will post 4.01 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,846 shares of company stock valued at $2,473,443. Insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.